Author

Kelly Pugh

Institutions: The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, Banner MD Anderson Cancer Center, Banner Gateway Medical Center, The Ohio State University

Observed institutions: The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, The Ohio State University Wexner Medical Center, Banner MD Anderson Cancer Center, Banner Gateway Medical Center, The Ohio State University

ORCID: 0009-0001-2913-9183

Observed ORCID: 0009-0001-2913-9183

OpenAlex ID: A5115008753

Reducing clinical trial eligibility barriers for patients with MDS: an icMDS position statement

2025 · Uma Borate, Kelly Pugh, et al. · Blood · 12

Inclusion, characteristics, and reporting of older patients in recent registration trials for DLBCL

2025 · Nina Rosa Neuendorff, Kelly Pugh, et al. · Blood Advances · 2

Safety of gemtuzumab ozogamicin with cytarabine, daunorubicin, and midostaurin induction in FLT3-mutated AML

2025 · Jayanshu Jain, Kelly Pugh, et al. · Blood Neoplasia · 1

Efficacy of Luspatercept on Transfusion Burden and Cytopenias in Intermediate, High, and Very High Risk Myelodysplastic Syndromes

2024 · Daniel Leonard, David Sallman, et al. · Blood · 1

CPX-351 in combination with ruxolitinib for advanced-phase myeloproliferative neoplasms: results of a phase 1 study

2026 · Shivani Handa, Yazan Madanat, et al. · Blood Neoplasia

Hematologic responses achieved with luspatercept in higher-risk myelodysplastic syndromes

2026 · Daniel Leonard, David A. Sallman, et al. · Blood Advances

Post-Transplant Cyclophosphamide with Tacrolimus/Sirolimus after RIC Allo-HCT from Matched Donors: A Single-Center Retrospective Study

2026 · Jesse Ritter, Olivia Triplett, et al. · Transplantation and Cellular Therapy

Wide variability and inconsistency in reporting of results of Myelodysplastic Syndromes/neoplasms (MDS) clinical trials: An icMDS systematic review of published manuscripts

2025 · Ted Getz, Kelly Pugh, et al. · Blood

AML-488: A Phase 1 Study of Gemtuzumab Ozogamicin Added to Cytarabine, Daunorubicin, and Midostaurin Induction in Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia

2025 · Jayanshu Jain, Kelly Pugh, et al. · Clinical Lymphoma Myeloma & Leukemia

POSTER: AML-488 A Phase 1 Study of Gemtuzumab Ozogamicin Added to Cytarabine, Daunorubicin, and Midostaurin Induction in Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia

2025 · Jayanshu Jain, Kelly Pugh, et al. · Clinical Lymphoma Myeloma & Leukemia

Real World Outcomes of Patients (Pts) with Acute Myeloid Leukemia, Myelodysplasia-Related (AML-MR) or Therapy-Related AML (t-AML) Receiving Venetoclax-Based Therapies

2024 · Kelly Pugh, Michael C Walker, et al. · Blood

Works count: 11

Citation count: 16

H-index: 2

I10-index: 1